{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:59:43Z","timestamp":1793401183388,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40123-026-01394-1","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T10:40:05Z","timestamp":1779187205000},"page":"2285-2303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prospective Real-World Outcomes After Switching to Aflibercept 8\u00a0mg in Neovascular Age-Related Macular Degeneration with High Treatment Burden"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct07390253","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1735-8372","authenticated-orcid":false,"given":"Christoph","family":"Spartalis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Ullrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Leisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Ruiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Pilwachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Findl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"1394_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218242","author":"F Ricci","year":"2020","unstructured":"Ricci F, Bandello F, Navarra P, Staurenghi G, Stumpp M, Zarbin M. Neovascular age-related macular degeneration: therapeutic management and new-upcoming approaches. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21218242.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1394_CR2","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1136\/bjophthalmol-2019-314422","volume":"104","author":"JQ Li","year":"2020","unstructured":"Li JQ, Welchowski T, Schmid M, Mauschitz MM, Holz FG, Finger RP. Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis. Br J Ophthalmol. 2020;104(8):1077\u201384.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"1394_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.mcna.2021.01.003","volume":"105","author":"CJ Thomas","year":"2021","unstructured":"Thomas CJ, Mirza RG, Gill MK. Age-related macular degeneration. Med Clin North Am. 2021;105(3):473\u201391.","journal-title":"Med Clin North Am"},{"issue":"5","key":"1394_CR4","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology. 2020;127(5):616\u201336.","journal-title":"Ophthalmology"},{"issue":"6","key":"1394_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40259-021-00499-2","volume":"35","author":"M Parravano","year":"2021","unstructured":"Parravano M, Costanzo E, Scondotto G, Trifiro G, Virgili G. Anti-VEGF and other novel therapies for neovascular age-related macular degeneration: an update. BioDrugs. 2021;35(6):673\u201392.","journal-title":"BioDrugs"},{"issue":"3","key":"1394_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10384-023-00985-w","volume":"67","author":"R Mori","year":"2023","unstructured":"Mori R, Honda S, Gomi F, et al. Efficacy, durability, and safety of faricimab up to every 16\u00a0weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase\u00a03 TENAYA trial. Jpn J Ophthalmol. 2023;67(3):301\u201310.","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"1394_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193\u2013201.","journal-title":"Ophthalmology"},{"key":"1394_CR8","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.2147\/OPTH.S409103","volume":"17","author":"G Reitan","year":"2023","unstructured":"Reitan G, Kjellevold Haugen IB, Andersen K, Bragadottir R, Bindesboll C. Through the eyes of patients: understanding treatment burden of intravitreal anti-VEGF injections for nAMD patients in Norway. Clin Ophthalmol. 2023;17:1465\u201374.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"1394_CR9","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1038\/s41598-019-38934-8","volume":"9","author":"T Wecker","year":"2019","unstructured":"Wecker T, Grundel B, Reichl S, et al. Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment. Sci Rep. 2019;9(1):3301.","journal-title":"Sci Rep"},{"issue":"6","key":"1394_CR10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/APO.0000000000000445","volume":"10","author":"V Chaikitmongkol","year":"2021","unstructured":"Chaikitmongkol V, Sagong M, Lai TYY, et al. Treat-and-extend regimens for the management of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: consensus and recommendations from the Asia-Pacific Vitreo-retina Society. Asia-Pac J Ophthalmol. 2021;10(6):507\u201318.","journal-title":"Asia-Pac J Ophthalmol"},{"issue":"10432","key":"1394_CR11","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, et al. Intravitreal aflibercept 8\u00a0mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase\u00a03 trial. Lancet. 2024;403(10432):1141\u201352.","journal-title":"Lancet"},{"issue":"2","key":"1394_CR12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1177\/24741264221150345","volume":"7","author":"JS Nielsen","year":"2023","unstructured":"Nielsen JS, Roberts CL, Saggau DD, Alliman KJ. High-dose aflibercept for neovascular AMD and DME in suboptimal responders to standard-dose aflibercept. J Vitreoretin Dis. 2023;7(2):116\u201324.","journal-title":"J Vitreoretin Dis"},{"issue":"10432","key":"1394_CR13","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","volume":"403","author":"DM Brown","year":"2024","unstructured":"Brown DM, Boyer DS, Do DV, et al. Intravitreal aflibercept 8\u00a0mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase\u00a02\/3 trial. Lancet. 2024;403(10432):1153\u201363.","journal-title":"Lancet"},{"issue":"6","key":"1394_CR14","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s10384-025-01229-9","volume":"69","author":"H Matsumoto","year":"2025","unstructured":"Matsumoto H, Hoshino J, Numaga S, Asatori Y, Akiyama H. Loading phase outcomes of intravitreal aflibercept 8\u00a0mg for treatment-naive neovascular age-related macular degeneration. Jpn J Ophthalmol. 2025;69(6):911\u20137.","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"1394_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40942-025-00665-6","volume":"11","author":"J Cattaneo","year":"2025","unstructured":"Cattaneo J, De Oliveira Figueiredo EC, Montesel A, Vermeirsch S, Eandi CM. Early real-world outcomes of intravitreal aflibercept 8\u00a0mg in treatment-naive neovascular AMD: AI-assisted fluid volume analysis. Int J Retina Vitreous. 2025;11(1):42.","journal-title":"Int J Retina Vitreous"},{"key":"1394_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2024-002091","author":"D Sambhara","year":"2025","unstructured":"Sambhara D, Vakharia P, Eichenbaum DA. Real-world efficacy and safety of 8\u00a0mg aflibercept in neovascular AMD: a case series. BMJ Open Ophthalmol. 2025. https:\/\/doi.org\/10.1136\/bmjophth-2024-002091.","journal-title":"BMJ Open Ophthalmol"},{"issue":"8","key":"1394_CR17","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.oret.2025.02.002","volume":"9","author":"S Bala","year":"2025","unstructured":"Bala S, Barbosa GCS, Mohan N, et al. Initial functional and anatomical outcomes of high-dose aflibercept 8\u00a0mg in exudative neovascular age-related macular degeneration. Ophthalmol Retina. 2025;9(8):756\u201366.","journal-title":"Ophthalmol Retina"},{"issue":"11","key":"1394_CR18","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1007\/s40123-025-01239-3","volume":"14","author":"N Bartolomeo","year":"2025","unstructured":"Bartolomeo N, Schuetz YP, Nascimbeni AC, et al. Early outcome analysis of intravitreal aflibercept 8\u00a0mg treatment in naive patients with neovascular age-related macular degeneration using artificial intelligence. Ophthalmol Ther. 2025;14(11):2819\u201329.","journal-title":"Ophthalmol Ther"},{"key":"1394_CR19","doi-asserted-by":"crossref","unstructured":"Liesenhoff C, Krause D, Eckardt F, et al. Wirksamkeit von 2\u00a0mg gegenuber hochdosierten 8\u00a0mg Aflibercept bei neovaskularer altersbedingter Makuladegeneration [Efficacy of 2\u2009mg vs. high-dose 8\u00a0mg aflibercept in neovascular age related macular degeneration]. Klin Monbl Augenheilkd. 2026;243(2):103\u2013109.","DOI":"10.1055\/a-2760-5850"},{"key":"1394_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-026-01344-x","author":"AM Kitay","year":"2026","unstructured":"Kitay AM, Tillmann A, Pfister I, et al. One-year real-world outcomes of switching to aflibercept 8\u00a0mg in eyes with neovascular age-related macular degeneration: a Swiss Retina Research Network Report. Ophthalmol Ther. 2026. https:\/\/doi.org\/10.1007\/s40123-026-01344-x.","journal-title":"Ophthalmol Ther"},{"key":"1394_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000004813","author":"RN Sather 3rd","year":"2026","unstructured":"Sather RN 3rd, Chiang T, Moon JY, Dev S, Belin PJ. Real-world durability of aflibercept 8\u00a0mg and faricimab in initiators versus switchers: a multicenter retrospective analysis. Retina. 2026. https:\/\/doi.org\/10.1097\/IAE.0000000000004813.","journal-title":"Retina"},{"issue":"4","key":"1394_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2026.101087","volume":"6","author":"J Spindler","year":"2026","unstructured":"Spindler J, Artemiev D, Pfister IB, et al. Twelve-month outcomes using aflibercept 8\u00a0mg in treatment-naive and pretreated diabetic macular edema: a Swiss Retina Research Network Report. Ophthalmology Science. 2026;6(4):101087.","journal-title":"Ophthalmology Science"},{"issue":"6","key":"1394_CR23","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamaophthalmol.2025.0969","volume":"143","author":"KE Binder","year":"2025","unstructured":"Binder KE, Bleidissel N, Charbel Issa P, Maier M, Coulibaly LM. Noninfectious intraocular inflammation after intravitreal aflibercept. JAMA Ophthalmol. 2025;143(6):499\u2013506.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"1394_CR24","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1186\/s12886-024-03788-w","volume":"24","author":"L Hoffmann","year":"2024","unstructured":"Hoffmann L, Michels S, Eandi C, Karam MA, Figueiredo ECO, Hatz K. Aflibercept high-dose (8mg) related intraocular inflammation (IOI)\u2014a case series. BMC Ophthalmol. 2024;24(1):520.","journal-title":"BMC Ophthalmol"},{"key":"1394_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-026-01349-6","author":"L Hoffmann","year":"2026","unstructured":"Hoffmann L, Hatz K. Lower rates of intraocular inflammation with aflibercept 8\u00a0mg delivered via pre-filled syringe versus vial. Ophthalmol Ther. 2026. https:\/\/doi.org\/10.1007\/s40123-026-01349-6.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"1394_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40942-025-00768-0","volume":"12","author":"LN Stoehr","year":"2025","unstructured":"Stoehr LN, Wakili P, Darwisch W, et al. Intraocular inflammation following aflibercept 8\u00a0mg: real-world data from a multicentre retrospective observational study. Int J Retina Vitreous. 2025;12(1):6.","journal-title":"Int J Retina Vitreous"},{"issue":"3","key":"1394_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.oret.2025.08.018","volume":"10","author":"M Lakhani","year":"2026","unstructured":"Lakhani M, Kwan ATH, Kundapur D, Popovic MM, Damji KF, Hurley BR. Association of anti-VEGF therapy with reported ocular adverse events: a global pharmacovigilance analysis. Ophthalmol Retina. 2026;10(3):265\u201382.","journal-title":"Ophthalmol Retina"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01394-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01394-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01394-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:24:30Z","timestamp":1782739470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01394-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1394"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01394-1","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"7 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Christoph Spartalis reports consultancy for Bayer. Oliver Findl is a scientific advisor to Carl Zeiss Meditec AG, Croma, and Johnson & Johnson. Marlies Ullrich, Silvia Winkler, Christoph Leisser, Manuel Ruiss, and Caroline Pilwachs declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the Ethics Committee of the City of Vienna (EK 24-105-0824, NCT07390253) and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants. No identifying participant information is included in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors thank the patients who participated in this study for their contribution to clinical research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Thanking Patient Participant(s)"}},{"value":"Patients were not involved in the design, conduct, reporting, or dissemination of this research.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Involvement"}}]}}